Migraine with aura

8 trials 5 recruiting MedDRA PT
8 Registered trials
5 Recruiting
2 Unique sponsors
2 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 7 Other: 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2022-501099-24-00 11 countries 2023 n=127
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2022-501100-94-00 10 countries 2023 n=163
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2022-501172-25-00 9 countries 2024 n=475
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2023-506029-12-00 10 countries 2024 n=1,013
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2023-507096-21-00 9 countries 2021 n=382
    Ended
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-512743-23-00 3 countries 2021 n=155
    Recruiting
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-512744-32-00 2 countries 2022 n=98
    Recruiting

Other

1 trial
  • Pfizer Inc. Commercial
    IMP not specified
    2025-525125-12-00 1 country 2026 n=36
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase III 2
Pfizer Inc. Commercial 3 Other, Phase III 3
New trials by year
2021
2
2022
1
2023
2
2024
2
2026
1
← All indication landscapes